<DOC>
	<DOCNO>NCT02095886</DOCNO>
	<brief_summary>The purpose study select best dose level ( amount drug give ) best formulation study drug ( BMS-955176 ) develop .</brief_summary>
	<brief_title>Relative Bioavailability Study With BMS-955176</brief_title>
	<detailed_description>Primary Purpose : Other : This study assess bioavailability BMS-955176 micronized crystalline ( MC ) tablet relative spray-dried dispersion ( SDD ) suspension . Assessment additional experimental formulation relative micronized crystalline tablet also perform</detailed_description>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Healthy subject determine clinically significant deviation normal medical history , physical examination , vital sign measurement , 12lead electrocardiogram ( ECG ) measurements clinical laboratory test result Body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive . BMI = Weight ( kg ) / [ height ( ) ] 2 Men woman , age 18 50 year , inclusive Women must childbearing potential , must breastfeed Any significant acute chronic medical illness History cardiac disease clinically significant cardiac arrhythmia Current recent ( within 3 month study drug administration ) gastrointestinal disease Any major surgery within 4 week study drug administration Any gastrointestinal surgery ( include cholecystectomy ) could impact upon absorption study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>